Nasal Spray News and Research

RSS

New influenza vaccine options for upcoming flu season

The next flu shot season will include several new vaccine options for consumers, Mayo Clinic vaccine expert Gregory Poland, M.D., says. Fearful of needles? There's now an influenza vaccination just for you. Allergic to eggs? It won't stop you from getting a flu shot. The new choices move influenza vaccinations closer to the personalized approach long sought by immunologists including Dr. Poland, but they may also prove bewildering to patients, he says.

16 Jul 2013

Allergic rhinitis treatments: an interview with Dr Dermot Ryan, GP and allergy expert

Allergic rhinitis is most commonly recognized as hay fever in the United Kingdom and it is due to the impact of an allergen, in the case of hay fever a pollen, setting off an inflammatory response in the lungs, causing typical symptoms...

5 Jun 2013

Research data on AMPYRA Extended Release Tablets to be presented at CMSC and ACTRIMS meeting

Acorda Therapeutics, Inc. will present new research data on AMPYRA (dalfampridine) Extended Release Tablets, 10 mg at the 5th Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis, being held in Orlando, FL, May 29 - June 1.

28 May 2013

Lightlake Therapeutics announces Phase II clinical trial results of nasal spray treatment for BED

Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.

23 May 2013

Lightlake to present Phase II clinical trial results of opioid antagonist nasal spray at APA Annual Meeting

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing addiction treatments, announced today that a scientific abstract based on results of the Company's Phase II clinical trial of its opioid antagonist nasal spray treatment for patients with Binge Eating Disorder has been accepted for presentation at the American Psychiatric Association Annual Meeting taking place in San Francisco, California, May 18-22, 2013.

27 Mar 2013

New vaccine proves highly effective against H5N1 virus

Until now most experimental vaccines against the highly lethal H5N1 avian influenza virus have lacked effectiveness. But a new vaccine has proven highly effective against the virus when tested in both mice and ferrets. It is also effective against the H9 subtype of avian influenza.

26 Mar 2013

New molecular compounds can kill the influenza virus

Simon Fraser University virologist Masahiro Niikura and his doctoral student Nicole Bance are among an international group of scientists that has discovered a new class of molecular compounds capable of killing the influenza virus.

22 Feb 2013

Otolaryngology, head and neck surgery: an interview with Thomas Cherry, Cook Medical

Cook Medical is the world’s largest privately held medical device manufacturer. The ENT division is Cook’s 10th business unit/clinical division and we are excited to meet the needs of ENT patients.

From COOK MEDICAL INC. 18 Feb 2013

Study: OEND effectively addresses epidemic of fatal opioid overdose

In a study of communities in Massachusetts with high numbers of opioid overdose deaths, the implementation of overdose education and naloxone distribution (OEND) was associated with a significant reduction in opioid overdose death rates.

2 Feb 2013

Common myths about flu from Mayo Clinic

It seems you can't go anywhere these days without hearing "the flu this" or "the flu that." Unfortunately, this season's influenza outbreak is one of the worst in years. And it's not just the flu virus that's causing problems; there are also many myths about the flu that are keeping people from doing more to prevent it.

29 Jan 2013

Flu virus can essentially tell time: Research

Scientists have discovered that that the flu virus can essentially tell time, thereby giving scientists the ability to reset the virus' clock and combat it in more effective ways. According to researchers at the Icahn School of Medicine at Mount Sinai, the flu knows how much time it has to multiply, infect other cells, and spread to another human being. If it leaves a cell too soon, the virus is too weak. If it leaves too late, the immune system has time to kill the virus.

18 Jan 2013

Acorda Therapeutics acquires Neuronex

Acorda Therapeutics, Inc. today announced that the Company has completed the acquisition of Neuronex, Inc., a privately held company developing a nasal spray formulation of diazepam. Under the terms of the agreement, Acorda paid $6.8 million to Neuronex to complete the acquisition.

21 Dec 2012

Oxytocin administration to fathers increases parental engagement with their infants

A large body of research has focused on the ability of oxytocin to facilitate social bonding in both marital and parenting relationships in human females. A new laboratory study, led by Dr. Ruth Feldman from Bar-Ilan University in Israel and published in the current issue of Biological Psychiatry, has found that oxytocin administration to fathers increases their parental engagement, with parallel effects observed in their infants.

11 Dec 2012

Nasal spray sufficient for allergic rhinitis in Japanese patients

Intranasal corticosteroid sprays can be administered as a first-line treatment for Japanese patients with seasonal allergic rhinitis, without the need to use systemic corticosteroid drugs, suggest study findings.

20 Nov 2012

Marinomed’s Antiviral polymer awarded Chinese patent

Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, today announced that it has been granted Chinese Patent No. CN101678040, entitled 'Antiviral polymer', by the Chinese patent office.

18 Nov 2012

Oxytocin regulates social distance between women and men

Flirting brings women and men closer. But the "social distance" ensures that they will keep a certain spatial distance from each other. Researchers under the leadership of the University of Bonn studied whether this distance can be diminished by the so-called love hormone, oxytocin.

16 Nov 2012

Teva announces additional data from QNASL Phase III program on seasonal allergic rhinitis

Teva Pharmaceutical Industries Ltd. announced today that additional data from the Phase III clinical program for QNASL- (beclomethasone dipropionate) Nasal Aerosol will be presented at the 2012 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Anaheim, CA on November 8-13, 2012.

7 Nov 2012